Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney.

Srivastava SP, Hedayat FA, Kanasaki K, Goodwin JE.

Front Pharmacol. 2019 Aug 16;10:904. doi: 10.3389/fphar.2019.00904. eCollection 2019. Review.

2.

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon.

Kanasaki K, Kawakita E, Koya D.

Front Pharmacol. 2019 May 16;10:476. doi: 10.3389/fphar.2019.00476. eCollection 2019. Review.

3.

Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice.

Takagaki Y, Shi S, Katoh M, Kitada M, Kanasaki K, Koya D.

Sci Rep. 2019 May 17;9(1):7519. doi: 10.1038/s41598-019-43730-5.

4.

βklotho is essential for the anti-endothelial mesenchymal transition effects of N-acetyl-seryl-aspartyl-lysyl-proline.

Gao R, Kanasaki K, Li J, Kitada M, Okazaki T, Koya D.

FEBS Open Bio. 2019 May;9(5):1029-1038. doi: 10.1002/2211-5463.12638. Epub 2019 Apr 22.

5.

N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m2.

Nitta K, Nagai T, Mizunuma Y, Kitada M, Nakagawa A, Sakurai M, Toyoda M, Haneda M, Kanasaki K, Koya D.

Clin Exp Nephrol. 2019 Aug;23(8):1004-1012. doi: 10.1007/s10157-019-01733-6. Epub 2019 Apr 4.

PMID:
30949886
6.

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Kanasaki K.

Clin Sci (Lond). 2019 Jan 15;133(1):151. doi: 10.1042/CS20180031_COR. Print 2019 Jan 15. No abstract available.

7.

Podoplanin+ tumor lymphatics are rate limiting for breast cancer metastasis.

Chen Y, Keskin D, Sugimoto H, Kanasaki K, Phillips PE, Bizarro L, Sharpe A, LeBleu VS, Kalluri R.

PLoS Biol. 2018 Dec 28;16(12):e2005907. doi: 10.1371/journal.pbio.2005907. eCollection 2018 Dec.

8.

Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.

Yang F, Takagaki Y, Yoshitomi Y, Ikeda T, Li J, Kitada M, Kumagai A, Kawakita E, Shi S, Kanasaki K, Koya D.

Cancer Res. 2019 Feb 15;79(4):735-746. doi: 10.1158/0008-5472.CAN-18-0620. Epub 2018 Dec 24.

PMID:
30584072
9.

AMP-Activated Protein (AMPK) in Pathophysiology of Pregnancy Complications.

Kumagai A, Itakura A, Koya D, Kanasaki K.

Int J Mol Sci. 2018 Oct 9;19(10). pii: E3076. doi: 10.3390/ijms19103076. Review.

10.

SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis.

Srivastava SP, Li J, Kitada M, Fujita H, Yamada Y, Goodwin JE, Kanasaki K, Koya D.

Cell Death Dis. 2018 Sep 24;9(10):997. doi: 10.1038/s41419-018-1057-0.

11.

Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice.

Parchem JG, Kanasaki K, Kanasaki M, Sugimoto H, Xie L, Hamano Y, Lee SB, Gattone VH, Parry S, Strauss JF, Garovic VD, McElrath TF, Lu KH, Sibai BM, LeBleu VS, Carmeliet P, Kalluri R.

J Clin Invest. 2018 Nov 1;128(11):5008-5017. doi: 10.1172/JCI99026. Epub 2018 Oct 8.

12.

Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.

Kitada M, Ogura Y, Nitta K, Fujii M, Kanasaki K, Konishi K, Iida Y, Nakagawa A, Koya D.

J Diabetes Investig. 2019 May;10(3):706-713. doi: 10.1111/jdi.12917. Epub 2018 Oct 1.

13.

BMP7 Signaling in TGFBR2-Deficient Stromal Cells Provokes Epithelial Carcinogenesis.

Eikesdal HP, Becker LM, Teng Y, Kizu A, Carstens JL, Kanasaki K, Sugimoto H, LeBleu VS, Kalluri R.

Mol Cancer Res. 2018 Oct;16(10):1568-1578. doi: 10.1158/1541-7786.MCR-18-0120. Epub 2018 Jun 22.

14.

Renal mitochondrial oxidative stress is enhanced by the reduction of Sirt3 activity, in Zucker diabetic fatty rats.

Ogura Y, Kitada M, Monno I, Kanasaki K, Watanabe A, Koya D.

Redox Rep. 2018 Dec;23(1):153-159. doi: 10.1080/13510002.2018.1487174.

PMID:
29897845
15.

Severe electrolytes disorders with the interstitial kidney alterations in the patient with the history of total thyroidectomy and parathyroidectomy: possible role of vitamin D deficiency.

Kawakita E, Kanasaki K, Hirai T, Tsuda SI, Watanabe A, Nitta K, Kitada M, Ogura Y, Takagaki Y, Fujii M, Nagai T, Shimada K, Takagi S, Mizunuma Y, Monno I, Shino F, Minato H, Miyatake N, Nakagawa A, Koya D.

Clin Case Rep. 2018 Apr 6;6(6):983-989. doi: 10.1002/ccr3.1500. eCollection 2018 Jun.

16.

A ketogenic amino acid rich diet benefits mitochondrial homeostasis by altering the AKT/4EBP1 and autophagy signaling pathways in the gastrocnemius and soleus.

Li J, Kanasaki M, Xu L, Kitada M, Nagao K, Adachi Y, Jinzu H, Noguchi Y, Kohno M, Kanasaki K, Koya D.

Biochim Biophys Acta Gen Subj. 2018 Jul;1862(7):1547-1555. doi: 10.1016/j.bbagen.2018.03.013. Epub 2018 Mar 15.

PMID:
29550428
17.

A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity.

Kitada M, Ogura Y, Suzuki T, Monno I, Kanasaki K, Watanabe A, Koya D.

Nutr Metab (Lond). 2018 Mar 2;15:20. doi: 10.1186/s12986-018-0255-1. eCollection 2018.

18.
19.

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.

Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T, Kanasaki K, Koya D.

J Diabetes Investig. 2018 Sep;9(5):1025-1032. doi: 10.1111/jdi.12802. Epub 2018 Mar 12.

20.

FGFR1 is essential for N-acetyl-seryl-aspartyl-lysyl-proline regulation of mitochondrial dynamics by upregulating microRNA let-7b-5p.

Hu Q, Li J, Nitta K, Kitada M, Nagai T, Kanasaki K, Koya D.

Biochem Biophys Res Commun. 2018 Jan 15;495(3):2214-2220. doi: 10.1016/j.bbrc.2017.12.089. Epub 2017 Dec 18.

PMID:
29269295
21.

The Effect of Piceatannol from Passion Fruit (Passiflora edulis) Seeds on Metabolic Health in Humans.

Kitada M, Ogura Y, Maruki-Uchida H, Sai M, Suzuki T, Kanasaki K, Hara Y, Seto H, Kuroshima Y, Monno I, Koya D.

Nutrients. 2017 Oct 18;9(10). pii: E1142. doi: 10.3390/nu9101142.

22.

Cyclic and intermittent very low-protein diet can have beneficial effects against advanced diabetic nephropathy in Wistar fatty (fa/fa) rats, an animal model of type 2 diabetes and obesity.

Kitada M, Ogura Y, Suzuki T, Monnno I, Kanasaki K, Watanabe A, Koya D.

Nephrology (Carlton). 2017 Dec;22(12):1030-1034. doi: 10.1111/nep.13152.

PMID:
28802091
23.

Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice.

Kanasaki M, Srivastava SP, Yang F, Xu L, Kudoh S, Kitada M, Ueki N, Kim H, Li J, Takeda S, Kanasaki K, Koya D.

Sci Rep. 2017 Aug 11;7(1):7927. doi: 10.1038/s41598-017-08513-w.

24.

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway.

Li J, Shi S, Srivastava SP, Kitada M, Nagai T, Nitta K, Kohno M, Kanasaki K, Koya D.

Cell Death Dis. 2017 Aug 3;8(8):e2965. doi: 10.1038/cddis.2017.353.

25.

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.

Kitada M, Tsuda SI, Konishi K, Takeda-Watanabe A, Fujii M, Kanasaki K, Nishizawa M, Nakagawa A, Koya D.

BMJ Open Diabetes Res Care. 2017 Jul 7;5(1):e000391. doi: 10.1136/bmjdrc-2017-000391. eCollection 2017. Erratum in: BMJ Open Diabetes Res Care. 2017 Sep 7;5(1):e000391corr1.

26.

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M.

Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31.

27.

Catechol-O-Methyltransferase Deficiency Leads to Hypersensitivity of the Pressor Response Against Angiotensin II.

Ueki N, Kanasaki K, Kanasaki M, Takeda S, Koya D.

Hypertension. 2017 Jun;69(6):1156-1164. doi: 10.1161/HYPERTENSIONAHA.117.09247. Epub 2017 May 1.

PMID:
28461606
28.

Restoration of the Hypothalamic-pituitary-adrenal Response to Hypoglycemia in Type 2 Diabetes by Avoiding Chronic Hypoglycemia.

Tsuda SI, Konishi K, Otoda T, Nagai T, Takeda-Watanabe A, Kanasaki M, Kitada M, Nakagawa A, Nishizawa M, Kanasaki K, Koya D.

Intern Med. 2016;55(23):3471-3473. Epub 2016 Dec 1.

29.

Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects.

Takagaki Y, Koya D, Kanasaki K.

Curr Opin Nephrol Hypertens. 2017 Jan;26(1):56-66. Review.

PMID:
27820706
30.

The pathological significance of dipeptidyl peptidase-4 in endothelial cell homeostasis and kidney fibrosis.

Kanasaki K.

Diabetol Int. 2016 Aug 3;7(3):212-220. doi: 10.1007/s13340-016-0281-z. eCollection 2016 Sep.

31.

Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.

Srivastava SP, Shi S, Kanasaki M, Nagai T, Kitada M, He J, Nakamura Y, Ishigaki Y, Kanasaki K, Koya D.

Sci Rep. 2016 Jul 18;6:29884. doi: 10.1038/srep29884.

32.

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.

Nitta K, Shi S, Nagai T, Kanasaki M, Kitada M, Srivastava SP, Haneda M, Kanasaki K, Koya D.

Biomed Res Int. 2016;2016:9172157. doi: 10.1155/2016/9172157. Epub 2016 Mar 20.

33.

A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity.

Kitada M, Ogura Y, Suzuki T, Sen S, Lee SM, Kanasaki K, Kume S, Koya D.

Diabetologia. 2016 Jun;59(6):1307-17. doi: 10.1007/s00125-016-3925-4. Epub 2016 Mar 28.

PMID:
27020449
34.

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes.

Shi S, Koya D, Kanasaki K.

Fibrogenesis Tissue Repair. 2016 Feb 13;9:1. doi: 10.1186/s13069-016-0038-0. eCollection 2016. Review.

35.

Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition.

Shi S, Kanasaki K, Koya D.

Biochem Biophys Res Commun. 2016 Feb 26;471(1):184-90. doi: 10.1016/j.bbrc.2016.01.154. Epub 2016 Jan 27.

36.

Concerted efforts to combat diabetic complications.

Kanasaki K.

Kidney Int. 2016 Feb;89(2):269-71. doi: 10.1016/j.kint.2015.12.023.

PMID:
26806828
37.

[Kidney fibrosis and endothelial injury].

Kanasaki K.

Nihon Jinzo Gakkai Shi. 2015;57(7):1200-5. Japanese. No abstract available.

PMID:
26665611
38.

The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia.

Ueki N, Takeda S, Koya D, Kanasaki K.

Int J Endocrinol. 2015;2015:572713. doi: 10.1155/2015/572713. Epub 2015 Apr 27. Review.

39.

Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.

Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, Nitta K, Takagi S, Kanasaki K, Koya D.

Kidney Int. 2015 Sep;88(3):479-89. doi: 10.1038/ki.2015.103. Epub 2015 Apr 1.

40.

Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.

Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T, Araki H, Koya D, Kanasaki K, Oiso Y, Goto M, Nishiyama A, Kobori H, Imai E, Ando M, Matsuo S.

Clin Exp Nephrol. 2015 Dec;19(6):1098-106. doi: 10.1007/s10157-015-1106-2. Epub 2015 Mar 21.

41.

Combating kidney fibrosis.

Kanasaki K, Maeshima A, Taduri G, Revuelta I.

Biomed Res Int. 2014;2014:679154. doi: 10.1155/2014/679154. Epub 2014 Sep 7. No abstract available.

42.

Lipid mediators in diabetic nephropathy.

Srivastava SP, Shi S, Koya D, Kanasaki K.

Fibrogenesis Tissue Repair. 2014 Sep 3;7:12. doi: 10.1186/1755-1536-7-12. eCollection 2014. Review.

43.

The role of ubiquitination and sumoylation in diabetic nephropathy.

Gao C, Huang W, Kanasaki K, Xu Y.

Biomed Res Int. 2014;2014:160692. doi: 10.1155/2014/160692. Epub 2014 Jun 4. Review.

44.

Low-protein diet for diabetic nephropathy.

Otoda T, Kanasaki K, Koya D.

Curr Diab Rep. 2014;14(9):523. doi: 10.1007/s11892-014-0523-z. Review.

PMID:
24986448
45.

The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Nagai T, Nitta K, Kanasaki M, Koya D, Kanasaki K.

Clin Exp Nephrol. 2015 Feb;19(1):65-74. doi: 10.1007/s10157-014-1000-3. Epub 2014 Jul 1. Review.

PMID:
24975544
46.

Clinical therapeutic strategies for early stage of diabetic kidney disease.

Kitada M, Kanasaki K, Koya D.

World J Diabetes. 2014 Jun 15;5(3):342-56. doi: 10.4239/wjd.v5.i3.342. Review.

47.

Cancer biology in diabetes.

Sen S, He Y, Koya D, Kanasaki K.

J Diabetes Investig. 2014 May 4;5(3):251-64. doi: 10.1111/jdi.12208. Epub 2014 Mar 5. Review.

48.

Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients.

Kanasaki K, Konishi K, Hayashi R, Shiroeda H, Nomura T, Nakagawa A, Nagai T, Takeda-Watanabe A, Ito H, Tsuda S, Kitada M, Fujii M, Kanasaki M, Nishizawa M, Nakano Y, Tomita Y, Ueda N, Kosaka T, Koya D.

J Diabetes Investig. 2013 Nov 27;4(6):673-5. doi: 10.1111/jdi.12095. Epub 2013 May 8.

49.

N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.

Nagai T, Kanasaki M, Srivastava SP, Nakamura Y, Ishigaki Y, Kitada M, Shi S, Kanasaki K, Koya D.

Biomed Res Int. 2014;2014:696475. doi: 10.1155/2014/696475. Epub 2014 Mar 24.

50.

N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Kanasaki K, Nagai T, Nitta K, Kitada M, Koya D.

Front Pharmacol. 2014 Apr 14;5:70. doi: 10.3389/fphar.2014.00070. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center